Harm Reduction in HIV Primary Care for PLWH Who Use Drugs

Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorUniversity of Pittsburgh

About this trial

People living with HIV (PLWH) who use drugs experience significant health disparities including lower rates of retention in HIV care and higher rates of unsuppressed viral load, resulting in secondary infections and increased mortality. The proposed study will used mixed methods to explore (a) the relationship between healthcare providers' attitudes towards working with PLWH who use drugs and providers' acceptance and practice of structural and relational harm reduction; (b) the degree to which relational harm reduction moderates the effect of intersectional stigma experienced in healthcare settings on patients' perceptions of their relationship with providers; (c) the degree to which structural HR moderates the relationship between the patient-provider relationship and clinical outcomes, and (d) whether patient-perceived HR approaches to care are directly associated with HIV clinical outcomes. The study will also use these findings to inform the development and pre-testing of an intervention to operationalize harm reduction in HIV clinical settings, using stakeholder-engaged and human-centered design approaches, presenting a novel path to reducing HIV health inequities for PLWH who use drugs.

Eligibility criteria

Qualifiers

Providers' Inclusion Criteria

Working at one of our 3 study sites (UPMC HIV/AIDS Program, Positive Health Clinic, or 1917 Clinic) or one of their partner sites offering substance use treatment (Internal Medicine Recovery Engagement Program, Center for Inclusion Health, or UAB's Outpatient-Based Opioid Treatment Clinic) for at least one year

Providing service or care to PLWH or people who use drugs at high risk for HIV acquisition

Working in one of the following positions: front desk/patient engagement, social worker, nurse, medical assistant, advanced practice provider, or physician

Disqualifiers

None

Trial design

Treatments tested in this trial

  • Harm Reduction

Treatment groups

768 Participants
are divided into 2 treatment groups

Sponsors and collaborators

University of Pittsburgh

Lead sponsor

Allegheny Health Network

Collaborator

University of Alabama at Birmingham

Collaborator

National Institute on Drug Abuse (NIDA)

Collaborator

National Institutes of Health (NIH)

Collaborator